logo
Plus   Neg
Share
Email

SKECHERS USA Issues Weak Q2 Guidance; Shares Slip

SKECHERS USA, Inc. (SKX) announced, for the second quarter of 2019, the company expects sales in the range of $1.200 billion to $1.225 billion, and earnings per share of $0.30 to $0.35. Analysts polled by Thomson Reuters expect the company to report profit per share of $0.38 on revenue of $1.23 billion. Analysts' estimates typically exclude special items.

For the first-quarter, the company reported net earnings of $108.8 million and earnings per share of $0.71 compared to $117.7 million or $0.75 per share, prior year. In the first quarter, effective income tax rate was 19.5 percent, reflecting the negative impact of several discrete items, totaling $0.02 per share. On average, 10 analysts polled by Thomson Reuters expected the company to report profit per share of $0.72 for the quarter. Earnings from operations was $165.9 million, an increase of 11.5 percent.

First-quarter sales grew 2.1 percent, or 5.2 percent on a constant currency basis, to $1.28 billion as a result of a 9.3 percent increase in the international business, partially offset by a 6.3 percent decrease in domestic business. On a constant currency basis, international business increased 15.0 percent. Analysts expected revenue of $1.3 billion for the quarter.

Shares of SKECHERS USA were down more than 12% in pre-market trade on Thursday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement. Supermarket chain Wegmans Food Markets, Inc. is recalling select Valencia oranges, lemons, and various other products containing fresh lemon citing potential contamination with Listeria monocytogenes, the U.S. Food and Drug Administration announced. The recall was initiated after Wegmans' lemons and oranges supplier Freshouse Produce LLC, issued a recall of its supplies.
RELATED NEWS
Follow RTT